These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 32443141

  • 1. Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections.
    Stewart AG, Harris PNA, Henderson A, Schembri MA, Paterson DL.
    J Antimicrob Chemother; 2020 Sep 01; 75(9):2384-2393. PubMed ID: 32443141
    [Abstract] [Full Text] [Related]

  • 2. Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections.
    Veeraraghavan B, Bakthavatchalam YD, Sahni RD.
    Infect Dis Ther; 2021 Dec 01; 10(4):1815-1835. PubMed ID: 34357517
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In Vivo Pharmacodynamic Profile of Ceftibuten-Clavulanate Combination against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in the Murine Thigh Infection Model.
    Abdelraouf K, Stainton SM, Nicolau DP.
    Antimicrob Agents Chemother; 2019 Jul 01; 63(7):. PubMed ID: 31061165
    [Abstract] [Full Text] [Related]

  • 6. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
    Afridi FI, Farooqi BJ.
    J Coll Physicians Surg Pak; 2012 Jun 01; 22(6):358-62. PubMed ID: 22630093
    [Abstract] [Full Text] [Related]

  • 7. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
    Sheu CC, Lin SY, Chang YT, Lee CY, Chen YH, Hsueh PR.
    Expert Rev Anti Infect Ther; 2018 Mar 01; 16(3):205-218. PubMed ID: 29402125
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing Escherichia coli.
    Al-Tamimi M, Abu-Raideh J, Albalawi H, Shalabi M, Saleh S.
    Microb Drug Resist; 2019 Oct 01; 25(8):1132-1141. PubMed ID: 31107146
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant Enterobacterales.
    Lomovskaya O, Rubio-Aparicio D, Tsivkovski R, Loutit J, Dudley M.
    Antimicrob Agents Chemother; 2022 Feb 15; 66(2):e0216821. PubMed ID: 34902261
    [Abstract] [Full Text] [Related]

  • 15. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
    Nguyen HM, Shier KL, Graber CJ.
    J Antimicrob Chemother; 2014 Apr 15; 69(4):871-80. PubMed ID: 24265230
    [Abstract] [Full Text] [Related]

  • 16. Molecular characterization of extended spectrum β -lactamases enterobacteriaceae causing lower urinary tract infection among pediatric population.
    Eltai NO, Al Thani AA, Al-Ansari K, Deshmukh AS, Wehedy E, Al-Hadidi SH, Yassine HM.
    Antimicrob Resist Infect Control; 2018 Apr 15; 7():90. PubMed ID: 30069306
    [Abstract] [Full Text] [Related]

  • 17. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years.
    Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S.
    World J Urol; 2016 Jul 15; 34(7):1031-7. PubMed ID: 26511749
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: A French prospective multicenter study.
    Madhi F, Jung C, Timsit S, Levy C, Biscardi S, Lorrot M, Grimprel E, Hees L, Craiu I, Galerne A, Dubos F, Cixous E, Hentgen V, Béchet S, Urinary-tract Infection due to Extended-Spectrum Beta-lactamase–producing Enterobacteriaceae in Children Group, Bonacorsi S, Cohen R.
    PLoS One; 2018 Jul 15; 13(1):e0190910. PubMed ID: 29370234
    [Abstract] [Full Text] [Related]

  • 20. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
    Raja NS.
    Int J Clin Pract; 2019 Sep 15; 73(9):1-5. PubMed ID: 31243859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.